BioSpace News Archive

VolitionRx Limited announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical Sciences, Small Animal Clinical Sciences Department will be presenting at the Veterinary Cancer Society Annual Conference in Houston taking place this weekend.

Isofol Medical AB, announced the successful completion of Japan’s Pharmaceutical and Medical Devices Agency review of the Clinical Trial Notification, allowing the start of the pivotal Phase 3 AGENT clinical study in metastatic colorectal cancer at Japanese sites.

Tampa General Hospital has opened a new 10,000-square-foot diagnostic center, located at 16521 U.S. 301 in Wimauma, that features an urgent care clinic, a primary care practice, diagnostic imaging and a laboratory..

United Health Products, Inc. announced that it has received the final report from an independent review of the results of its human clinical trial.

Cipher Pharmaceuticals Inc. announced it has received Health Canada approval, on October 10, 2019, for TRULANCE®, a Guanylate cyclase-C agonist in the form of a once-daily tablet for the treatment of adults with irritable bowel syndrome with constipation.

Castle Biosciences, Inc. announced the presentation of data supporting the ability of the DecisionDx®-Melanoma gene expression profile test to identify T1 melanoma patients at low risk for a positive sentinel lymph node at the American Society of Dermatopathology 56th Annual Meeting in San Diego from October 17-20.

Opinion Supports Use of KEYTRUDA, as Monotherapy or in Combination with Platinum and 5-Fluorouracil Chemotherapy, in Patients Whose Tumors Express PD-L (CPS ≥1)

Concept Medical B.V. with its headquarters in Tampa, Florida has announced that on 16th October 2019, they have received the CE certification for their MagicTouch group of products.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive trend vote on the Marketing Authorization Application (MAA) for fostamatinib disodium hexahydrate (fostamatinib)

Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) (“Auxly” or the “Company”) today announced that it has received approval from the TSX Venture Exchange (the “TSXV”) to amend the conversion price under its 6% unsecured convertible debentures in the principal amount of $100,000,000 maturing on January 16, 2020 (the “Debentures”) from $1.55 per share to $0.74 per share.